Harnessing the Human Immune System
Optimized human-derived antibodies against bacterial and viral infectious diseases, as well as cancer
Harnessing the Human Immune System
The immune system is nature’s most powerful weapon against disease. Trellis Bioscience is an NIH and venture-funded biotechnology company that leverages its proprietary CellSpot™ technology to derive rare, naturally optimized antibodies from healthy donor blood against infectious diseases and cancer.
Due to their human origin, our therapeutics are safer and more effective than alternatives.
Our Technology
Our Therapeutic Candidates
Trellis has derived five human monoclonal antibody (mAbs) therapeutics against bacterial, viral and cancer indications.
In vivo and in vitro experimental data show our antibodies possess superior binding affinity, broad-spectrum capabilities, and efficacy compared to alternative therapies
Biofilm is a leading cause of antibiotic resistance. This Scanning Electron Microscropy photograph at 4000X magnification shows our antibody, TRL1068, disrupting biofilm in Pseudomonas aeruginosa, a multi-drug resistant, gram-negative bacteria species.
Antibiotic Resistant
Antibiotic Susceptible
OUR COMPANY
We are business leaders and scientists passionate about developing human antibody therapies to various diseases.
Our team offers diverse academic and operational expertise, covering all stages of drug development:
1) Discovery
2) Preclinical Development
3) Clinical Trials
4) Commercialization
